Breaking News Instant updates and real-time market news.

MRK

Merck

$63.89

0.89 (1.41%)

08:04
05/19/17
05/19
08:04
05/19/17
08:04

Merck receives positive CHMP opinion recommending approval of Isentress 600mg

Merck announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a positive opinion recommending approval of ISENTRESS 600 mg film-coated tablets, in combination with other anti-retroviral medicinal products, for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 40 kg. In adults and pediatric patients, the recommended dosage is 1,200 mg once daily for treatment-naive patients or patients who are virologically suppressed on an initial regimen of ISENTRESS 400 mg twice daily. The recommendation will now be reviewed by the European Commission for marketing authorization in the European Union. A decision on approval is expected in the second half of 2017. The once daily formulation of ISENTRESS is currently under review in the United States by the Food and Drug Administration. The CHMP positive opinion was based on findings from the ONCEMRK trial, an ongoing Phase 3 multicenter, double-blind, randomized, active comparator-controlled clinical trial designed to evaluate the efficacy and safety of ISENTRESS 1200 mg, given as two 600 mg oral tablets once daily, compared to ISENTRESS 400 mg twice daily, each in combination with emtricitabine + tenofovir disoproxil fumarate in previously untreated HIV-1 infected adults. Once-daily ISENTRESS 600 mg, when used as part of an HIV-1 treatment regimen, demonstrated comparable efficacy and safety to ISENTRESS 400 mg twice a day after 48-weeks of treatment across a variety of patient populations.

  • 23

    May

  • 27

    May

  • 31

    May

  • 02

    Jun

  • 05

    Jun

  • 09

    Jun

  • 14

    Jun

MRK Merck
$63.89

0.89 (1.41%)

04/04/17
STFL
04/04/17
NO CHANGE
STFL
NewLink Genetics should be bought on weakness after data, says Stifel
Stifel analyst Stephen Willey said NewLink Genetics' (NLNK) combination of indoximod and Merck's (MRK) pembrolizumab in patients with treatment-naive melanoma demonstrated an overall response rate, or ORR, that is "essentially identical" to the previously-reported results from the Incyte (INCY)-Merck study of epacadostat/pembrolizumab. The lower rate of complete responses he doesn't "find terribly surprising" given what is already known about the current indoximod formulation, he tells investors. Willey, who views today's weakness as an interesting buying opportunity ahead of P1/2 data on the atezolizumab + GDC-0919 combination, keeps a Buy rating on Newlink shares.
04/20/17
JEFF
04/20/17
NO CHANGE
Target $51
JEFF
Underperform
Jefferies lowers Merck estimates, drops target to $51
Jefferies analyst Jeffrey Holford lowered his earnings estimates for Merck by up to 3% citing concerns on pricing for Januvia/Janumet. The analyst notes that his mid-term estimates are now up to 11% below consensus. Holford expects Keytruda, Januvia and Gardasil to miss expectations Q1. He cut his price target for Merck to $51 from $52 and keeps an Underperform rating on the name.
05/03/17
BMOC
05/03/17
NO CHANGE
BMOC
Merck results more positive than first appeared, says BMO Capital
BMO Capital analyst Alex Arfaei says he's more upbeat on Merck's Q1 results following its conference call. He says that the lower than expected Januvia revenue is "explainable," while the company's Keytruda drug looks set to beat expectations in 2H17. The analyst expects the company's 2017 results to come in at the top half of its guidance range, and he thinks the stock can rise, driven by Keytruda and its hepatitis C treatments. The analyst keeps an Outperform rating on the shares.
05/11/17
BMOC
05/11/17
NO CHANGE
BMOC
Merck Keytruda approval positive, says BMO Capital
BMO Capital analyst Alex Arfaei notes that the FDA approved Keytruda + chemo in first line NSCLC. The analyst says that the label is "solid," and he expects "strong uptake" for the drug in the condition, based on his checks with oncologists. The analyst raised his price target on the shares to $74 from $71 and keeps an Outperform rating on the stock.

TODAY'S FREE FLY STORIES

JUNO

Juno Therapeutics

$23.30

-2.22 (-8.70%)

18:11
05/26/17
05/26
18:11
05/26/17
18:11
Hot Stocks
Juno Therapeutics director acquires 20,000 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

UNH

UnitedHealth

$177.50

-0.55 (-0.31%)

18:06
05/26/17
05/26
18:06
05/26/17
18:06
Hot Stocks
UnitedHealth's OptumHealth awarded $200.5M government contract »

UnitedHealth's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    May

VEC

Vectrus

$29.62

0.02 (0.07%)

17:56
05/26/17
05/26
17:56
05/26/17
17:56
Hot Stocks
Vectrus Systems awarded $212.03M modification to government contract »

Vectrus Systems was…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IMMY

Imprimis

$3.34

-0.06 (-1.76%)

17:52
05/26/17
05/26
17:52
05/26/17
17:52
Syndicate
Breaking Syndicate news story on Imprimis »

Imprimis files $75M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

IRCP

IRSA Propiedades Comerciales

$43.58

-0.33 (-0.75%)

17:51
05/26/17
05/26
17:51
05/26/17
17:51
Syndicate
Breaking Syndicate news story on IRSA Propiedades Comerciales »

IRSA Propiedades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DSKE

Daseke

$9.79

-0.11 (-1.11%)

17:44
05/26/17
05/26
17:44
05/26/17
17:44
Syndicate
Breaking Syndicate news story on Daseke »

Daseke files $300M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ECYT

Endocyte

$2.47

0.02 (0.82%)

, RNN

Rexahn

$4.04

0.09 (2.28%)

17:35
05/26/17
05/26
17:35
05/26/17
17:35
Hot Stocks
On The Fly: After Hours Movers »

HIGHER: Endocyte (ECYT),…

ECYT

Endocyte

$2.47

0.02 (0.82%)

RNN

Rexahn

$4.04

0.09 (2.28%)

TGTX

TG Therapeutics

$12.05

0.15 (1.26%)

SGMO

Sangamo

$7.25

-0.55 (-7.05%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 22

    Jun

ECYT

Endocyte

$2.47

0.02 (0.82%)

17:33
05/26/17
05/26
17:33
05/26/17
17:33
Hot Stocks
Endocyte to announce updated data on EC1456, EC1169 at ASCO »

Endocyte announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

PEP

PepsiCo

$117.91

0.38 (0.32%)

17:30
05/26/17
05/26
17:30
05/26/17
17:30
Periodicals
PepsiCo in talks to acquire Vita Coco owner All Market, Reuters reports »

PepsiCo is in discussions…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCOV

Brightcove

$6.25

0.25 (4.17%)

17:25
05/26/17
05/26
17:25
05/26/17
17:25
Hot Stocks
Breaking Hot Stocks news story on Brightcove »

ESW Capital reports 8.08%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

SHIP

Seanergy Marine

$0.69

0.001244 (0.18%)

17:19
05/26/17
05/26
17:19
05/26/17
17:19
Hot Stocks
Seanergy Marine receives Nasdaq notice »

Seanergy Maritime…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

F

Ford

$10.93

0.07 (0.64%)

, DB

Deutsche Bank

$18.46

-0.39 (-2.07%)

17:10
05/26/17
05/26
17:10
05/26/17
17:10
General news
S&P advances to end week at record as Fed signals no rush to normalize policy »

The S&P 500 (SPX)…

F

Ford

$10.93

0.07 (0.64%)

DB

Deutsche Bank

$18.46

-0.39 (-2.07%)

BBY

Best Buy

$58.97

-2.28 (-3.72%)

HPQ

HP Inc.

$18.47

0.1 (0.54%)

BX

Blackstone

$32.58

0.11 (0.34%)

NOK

Nokia

$6.38

-0.02 (-0.31%)

AAPL

Apple

$153.61

-0.26 (-0.17%)

GM

General Motors

$33.07

0.47 (1.44%)

HUN

Huntsman

$24.75

-0.11 (-0.44%)

BF.A

Brown-Forman, also tag with BFA, BFB

$52.49

-0.21 (-0.40%)

BF.B

Brown-Forman, also tag with BFA, BFB

$51.73

0.13 (0.25%)

STZ

Constellation Brands

$180.93

0.79 (0.44%)

LOW

Lowe's

$80.91

-0.42 (-0.52%)

TIF

Tiffany

$86.18

0.36 (0.42%)

SHLD

Sears

$7.78

-0.7 (-8.25%)

SIG

Signet Jewelers

$49.31

-0.99 (-1.97%)

COST

Costco

$177.86

3.13 (1.79%)

ANF

Abercrombie & Fitch

$13.22

-0.83 (-5.91%)

AEO

American Eagle

$11.50

0.08 (0.70%)

EXPR

Express

$7.85

0.03 (0.38%)

TTWO

Take-Two

$77.07

-1.46 (-1.86%)

AZO

AutoZone

$615.62

8.28 (1.36%)

DSW

DSW

$16.73

-0.06 (-0.36%)

INTU

Intuit

$138.56

0.2 (0.14%)

PBYI

Puma Biotechnology

$79.75

1.7 (2.18%)

CHS

Chico's

$9.37

-0.39 (-4.00%)

SPLS

Staples

$8.98

-0.08 (-0.88%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 31

    May

  • 31

    May

  • 01

    Jun

  • 01

    Jun

  • 01

    Jun

  • 02

    Jun

  • 06

    Jun

  • 06

    Jun

  • 06

    Jun

  • 07

    Jun

  • 12

    Jun

  • 12

    Jun

  • 13

    Jun

  • 20

    Jun

  • 28

    Jun

  • 21

    Jul

BGNE

BeiGene

$37.42

-0.04 (-0.11%)

17:07
05/26/17
05/26
17:07
05/26/17
17:07
Syndicate
Breaking Syndicate news story on BeiGene »

BeiGene files automatic…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 06

    Jun

CGI

Celadon Group

17:06
05/26/17
05/26
17:06
05/26/17
17:06
Hot Stocks
Breaking Hot Stocks news story on Celadon Group »

Litespeed Management…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRD

Crawford & Company Inc.

, CRDA

Crawford & Co.

$7.65

0.01 (0.13%)

17:05
05/26/17
05/26
17:05
05/26/17
17:05
Hot Stocks
Crawford & Company COO Robinson to leave company »

Crawford & Company…

CRD

Crawford & Company Inc.

CRDA

Crawford & Co.

$7.65

0.01 (0.13%)

CRDB

Crawford & Company

$9.08

-0.02 (-0.22%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SEAS

SeaWorld

$18.08

-0.13 (-0.71%)

17:03
05/26/17
05/26
17:03
05/26/17
17:03
Hot Stocks
Breaking Hot Stocks news story on SeaWorld »

Hill Path Capital raises…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DMRC

Digimarc

$36.10

2.45 (7.28%)

17:03
05/26/17
05/26
17:03
05/26/17
17:03
Syndicate
Breaking Syndicate news story on Digimarc »

Digimarc files $100M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    May

  • 31

    May

  • 06

    Sep

IPCI

Intellipharmaceutics

$1.94

-0.01 (-0.51%)

17:01
05/26/17
05/26
17:01
05/26/17
17:01
Syndicate
Breaking Syndicate news story on Intellipharmaceutics »

Intellipharmaceutics…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Sep

GWR

Genesee & Wyoming

$66.47

0.91 (1.39%)

16:57
05/26/17
05/26
16:57
05/26/17
16:57
Hot Stocks
Genesee & Wyoming CEO Hellmann named chairman of the board »

Genesee & Wyoming…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PZG

Paramount Gold Nevada

$1.61

0.02 (1.26%)

16:54
05/26/17
05/26
16:54
05/26/17
16:54
Syndicate
Breaking Syndicate news story on Paramount Gold Nevada »

Paramount Gold Nevada…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SGMO

Sangamo

$7.25

-0.55 (-7.05%)

16:53
05/26/17
05/26
16:53
05/26/17
16:53
Syndicate
Breaking Syndicate news story on Sangamo »

Sangamo files $200M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

TGTX

TG Therapeutics

$12.05

0.15 (1.26%)

16:49
05/26/17
05/26
16:49
05/26/17
16:49
Syndicate
Breaking Syndicate news story on TG Therapeutics »

TG Therapeutics files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Jun

  • 05

    Jun

  • 05

    Jun

  • 06

    Jun

  • 22

    Jun

AVXL

Anavex

$5.88

-0.06 (-1.01%)

16:49
05/26/17
05/26
16:49
05/26/17
16:49
Syndicate
Breaking Syndicate news story on Anavex »

Anavex files to sell 5M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EIG

Employers Holdings

$39.95

-0.4 (-0.99%)

16:42
05/26/17
05/26
16:42
05/26/17
16:42
Syndicate
Breaking Syndicate news story on Employers Holdings »

Employers Holdings files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RNN

Rexahn

$4.04

0.09 (2.28%)

16:41
05/26/17
05/26
16:41
05/26/17
16:41
Syndicate
Breaking Syndicate news story on Rexahn »

Rexahn files $150M mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.